We've invested in groundbreaking technologies and platforms that aim
to deliver better solutions to our patients. These include
protein-based technologies that enhance the therapeutic potential of
antibodies by combining them with small molecule drugs.
Antibody Drug Conjugates (ADCs)
This technology platform uses the targeting of an antibody to
deliver a therapeutic agent. ADC technology is more traditionally used
in oncology; however, by coupling a highly potent immunomodulator to
an anti-inflammatory monoclonal antibody, it can be delivered to
dysregulated immune cells with the goal to turn down inflammation,
restore normal immune function and spare normal tissue. By combining
AbbVie’s expertise in discovering and developing specific monoclonal
antibodies with our experience in small molecule chemistry – AbbVie is
leading the field in applying ADC technology to immune-mediated diseases.
We've also concentrated our efforts on boosting the therapeutic
potential of specific small molecule inhibitors by generating
combinations of small molecule approaches in fixed dose combinations.
Targeted drug delivery is a vital avenue of our research because it
can change the fundamental way diseases are treated. We are exploring
several new methods for delivering medicines.
Other research targets include: